LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells

Xiang Chen,Li Pan,Jia Wei,Ruijie Zhang,Xiaozhi Yang,Jinhua Song,Ren-Yuan Bai,Shengling Fu,Christopher R. Pierson,Jonathan L. Finlay,Chenglong Li,Jiayuh Lin

DOI: https://doi.org/10.1038/s41598-021-85888-x

IF: 4.6

2021-03-22

Scientific Reports

Abstract:Abstract Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor and an oncogene product, which plays a pivotal role in tumor progression. Therefore, targeting persistent STAT3 signaling directly is an attractive anticancer strategy. The aim of this study is to test the efficacy of a novel STAT3 small molecule inhibitor, LLL12B, in suppressing medulloblastoma cells in vitro and tumor growth in vivo. LLL12B selectively inhibited the induction of STAT3 phosphorylation by interleukin-6 but not induction of STAT1 phosphorylation by INF-γ. LLL12B also induced apoptosis in human medulloblastoma cells. In addition, LLL12B exhibited good oral bioavailability in vivo and potent suppressive activity in tumor growth of medulloblastoma cells in vivo. Besides, combining LLL12B with cisplatin showed greater inhibition of cell viability and tumorsphere formation as well as induction of apoptosis comparing to single agent treatment in medulloblastoma cells. Furthermore, LLL12B and cisplatin combination exhibited greater suppression of medulloblastoma tumor growth than monotherapy in vivo. The present study supported that LLL12B is a novel therapeutic agent for medulloblastoma and the combination of LLL12B with a chemotherapeutic agent cisplatin may be an effective approach for medulloblastoma therapy.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper aims to address the development of a novel small molecule inhibitor, LLL12B, to effectively inhibit the growth of medulloblastoma cells and enhance the cytotoxic effects of cisplatin. Specifically, the paper aims to: 1. **Validate the inhibitory effect of LLL12B on the STAT3 signaling pathway**: Through in vitro experiments, verify whether LLL12B can selectively inhibit IL-6-induced STAT3 phosphorylation without affecting INF-γ-induced STAT1 phosphorylation. 2. **Evaluate the biological effects of LLL12B in medulloblastoma cells**: Investigate whether LLL12B can induce apoptosis in medulloblastoma cells and inhibit their proliferation and tumor sphere formation ability. 3. **Test the synergistic effect of LLL12B in combination with cisplatin**: Explore whether the combination of LLL12B and cisplatin can more effectively inhibit the survival and tumor sphere formation of medulloblastoma cells, and whether it can more significantly inhibit tumor growth in in vivo experiments. 4. **Evaluate the in vivo pharmacokinetic properties of LLL12B**: Study the bioavailability and pharmacokinetic properties of LLL12B in mice to assess its feasibility as a potential therapeutic drug. Through these studies, the paper aims to provide a new strategy for the treatment of medulloblastoma, particularly in combination with the existing chemotherapeutic drug cisplatin, to improve therapeutic efficacy and reduce long-term neurotoxic side effects.

LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells

A Novel Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Activities and Exhibits Potent Growth-Suppressive Activity in

A Novel Small Molecular STAT3 Inhibitor, LY5, Inhibits Cell Viability, Cell Migration, and Angiogenesis in Medulloblastoma Cells

Small-molecule Compounds Targeting the STAT3 DNA-binding Domain Suppress Survival of Cisplatin-Resistant Human Ovarian Cancer Cells by Inducing Apoptosis.

LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer

LL1, a Novel and Highly Selective STAT3 Inhibitor, Displays Anti‐colorectal Cancer Activities in Vitro and in Vivo

L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in Vitro and in Vivo

A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells

Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.

Honokiol-Chlorambucil Co-Prodrugs Selectively Enhance the Killing Effect Through STAT3 Binding on Lymphocytic Leukemia Cells in Vitro and in Vivo

Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells.

Preclinical Characterization of WB737, a Potent and Selective STAT3 Inhibitor, in Natural Killer/t-Cell Lymphoma

A Novel Small Molecular STAT3 Inhibitor, 5Br-6B, Induces Apoptosis and Inhibits Migration in Colorectal Cancer Cells

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality with BTK or MDM2-P53 Inhibitor in Diffuse Large B-Cell Lymphoma.

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

Small-molecule Inhibitors Targeting the DNA-binding Domain of STAT3 Suppress Tumor Growth, Metastasis and STAT3 Target Gene Expression in Vivo

DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway

A Novel Silicone Derivative of Natural Osalmid (DCZ0858) Induces Apoptosis and Cell Cycle Arrest in Diffuse Large B-cell Lymphoma Via the JAK2/STAT3 Pathway

Expression of Leukemia-Inhibitory Factor As an Autocrinal Growth Factor in Human Medulloblastomas

Anlotinib Potentially Eliminates Leukemia Stem Cells and Modulates the Chemosensitivity via Inhibiting JAK2-STAT3/5 Signaling

Abstract 3252: A Novel Small Molecule, LY5, Selectively Inhibits STAT3 Phosphorylation and Activities and Exhibits Potent Growth Suppressive Activity in Cancer Cells.